- --------------------------------------------------------------------------------
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
--------------------
FORM 8-K
CURRENT REPORT
PURSUANT TO
SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): APRIL 18, 2000
--------------------
GENOME THERAPEUTICS CORP.
(Exact name of registrant as specified in its charter)
MASSACHUSETTS 0-10824 04-2297484
(State or other jurisdiction (Commission File Number) (I.R.S. Employer
of incorporation) Identification Number)
100 BEAVER STREET
WALTHAM, MASSACHUSETTS 02453
(Address, of principal executive offices, including zip code)
(781) 398-2300
(Registrant's Telephone number including area code)
--------------------
- --------------------------------------------------------------------------------
Item 5. OTHER EVENTS
On April 13, 2000, Genome Therapeutics Corp. issued a press release
announcing that it would not proceed with its follow-on public offering and
that it would file an amendment to the registration statement that it filed
with the Securities and Exchange Commission on March 16, 2000 to convert it
to a shelf registration statement. A copy of this press release is attached
to this Current Report on Form 8-K as Exhibit 99.1.
-2-
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
GENOME THERAPEUTICS CORP.
By /s/ Robert J. Hennessey
---------------------------------
Title: Chairman of the Board and
Chief Executive Officer
Date: April 18, 2000
-3-
EXHIBIT INDEX
99.1 Press Release dated April 13, 2000
-4-